Inspira Pharmaceuticals - Revision history

95.149.241.133 at 03:47, 20 August 2022

2022-08-20T03:47:08Z

← Older revision		Revision as of 04:47, 20 August 2022
Line 51:		Line 51:
	[[Category:Thesis]]		[[Category:Thesis]]
	[[Category:Equities]]		[[Category:Equities]]

			__INDEX__

>Louis at 17:46, 22 July 2022

2022-07-22T17:46:59Z

← Older revision		Revision as of 18:46, 22 July 2022
Line 49:		Line 49:

	A skilled protein scientist with over 15 years of hands-on expertise, Neil advises on the key experiments that drive our technology forward, leveraging his practical expertise in biotech consultancy & entrepreneurship. PhD from the Institute of Cancer Research, University of London.		A skilled protein scientist with over 15 years of hands-on expertise, Neil advises on the key experiments that drive our technology forward, leveraging his practical expertise in biotech consultancy & entrepreneurship. PhD from the Institute of Cancer Research, University of London.
			[[Category:Thesis]]
			[[Category:Equities]]

172.18.0.3: /* Idea */

2022-05-17T16:03:25Z

Idea

← Older revision		Revision as of 17:03, 17 May 2022
Line 10:		Line 10:
	==Idea==		==Idea==

	<~~html~~>		<vimeo>516786673</vimeo>
	<~~iframe width="560" height="315" src="https:/~~/~~player.~~vimeo~~.com/video/516786673?h=3da816a341" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>~~
	~~</html~~>

	There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).		There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).

94.119.64.2: /* Idea */

2022-04-05T08:50:50Z

Idea

← Older revision		Revision as of 09:50, 5 April 2022
Line 11:		Line 11:

	<html>		<html>
	<iframe width="560" height="315" src="https://vimeo.com/516786673/3da816a341" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>		<iframe width="560" height="315" src="https://player.vimeo.com/video/516786673?h=3da816a341" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
	</html>		</html>

94.119.64.2: Created page with "==Summary== Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans. * Patent protected plant-based formulations (under license) * Proven to kill SARS-CoV-2 in early stage lab testing * Platform technology - Potential for a range of lung diseases..."

2022-04-05T08:49:54Z

Created page with "==Summary== Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans. * Patent protected plant-based formulations (under license) * Proven to kill SARS-CoV-2 in early stage lab testing * Platform technology - Potential for a range of lung diseases..."

New page

==Summary==

Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans.

* Patent protected plant-based formulations (under license)
* Proven to kill SARS-CoV-2 in early stage lab testing
* Platform technology - Potential for a range of lung diseases
* Working with leading research organisations

==Idea==

<html>
<iframe width="560" height="315" src="https://vimeo.com/516786673/3da816a341" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
</html>

There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).

Our team were conducting research into wound care with another biomedical firm but, when COVID-19 hit, they looked to pivot the technology through Inspira to tackle this challenge. They discovered that the molecules in the formulations might be able to attack the SARS-CoV-2 spike proteins.

In lab tests, our formulations killed over 95% of the SARS-CoV-2 virus; now we want to test whether a COVID-19 patient could safely inhale our formulations directly into the lungs as an effective treatment.

So far we've secured cornerstone investment from biotech angel investors & a Singaporean VC, we’re now offering retail investors the opportunity to invest alongside them! Funds raised will be used to test our formulations as a potential new drug. This will include further laboratory analysis, safety testing, & preparation for human trials.

We believe our technology has further potential for a number of other respiratory infections. We plan to test our formulations against cystic fibrosis, influenza & the common cold in coming months.

COVID-19 thrives in a crowd, wouldn't it be amazing if the crowd could come together to fight back against the pandemic.

==Team==

'''Rory McGoldrick'''

Co-Founder & CEO

Rory founded Inspira to see if small biotech could find a cure for deadly respiratory diseases, including COVID-19. A qualified lawyer with experience in corporate finance, start-ups & commercial law. Previously founded Metan Polska, a European clean-tech company that was awarded a €5 mil R&D grant in 2020. Rory is driven by both social benefits & shareholder returns.

'''Nick Woolf (PT)'''

Co-Founder & Director

Nick is an accomplished leader in life sciences with experience in biotech & investment banking. Nick was previously CEO of AusCann Group (ASX:AC8) & has held senior executive roles with SUDA Pharmaceuticals & Oxford BioMedica. MA (Oxon) in Chemistry from Oxford University.

'''Dr Giuseppe Trigiante (PT)'''

Scientific Advisor

A specialist biochemist with an inventive mindset, Giuseppe has been instrumental in developing Inspira’s core technology. He's the inventor of a process that preserves the activity of the active molecules in liquid solution. He's led the company’s scientific team since Inspira’s inception. PhD from Stanford University.

'''Dr Neil Rzechorzek (PT)'''

Scientific Advisor

A skilled protein scientist with over 15 years of hands-on expertise, Neil advises on the key experiments that drive our technology forward, leveraging his practical expertise in biotech consultancy & entrepreneurship. PhD from the Institute of Cancer Research, University of London.